8-K
filed May 27, 2026, 4:15 PM ET
ticker PASG
CIK 0001787297
other material
confidence high
sentiment neutral
materiality 0.55
Passage Bio terminates Gemma collaboration and exits Philadelphia office lease with $2.3M fee
Passage BIO, Inc.
- Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, effective May 21, 2026.
- Termination also eliminates options for four new CNS indications under the July 2024 agreement.
- Paid $2.3M to exit 37,000 sq ft office lease (originally expiring Dec 2031); company is remote-only.
- Subleases previously covered substantially all of that office space.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-26-066956
- form_type
- 8-K
- ticker
- PASG
- cik
- 0001787297
- company_name
- Passage BIO, Inc.
- filed_at
- 2026-05-27T20:15:26+00:00
- discovered_at
- 2026-05-27T20:17:00.415435+00:00
- generated_at
- 2026-05-27T20:21:19.798834+00:00
- sec_items
- ["1.02"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.55
- calibrated_materiality_score
- 0.55
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-26-066956
- json_url
- https://secwatch.observer/filing/0001104659-26-066956.json
- markdown_url
- https://secwatch.observer/filing/0001104659-26-066956.md
- text_url
- https://secwatch.observer/filing/0001104659-26-066956.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/0001104659-26-066956-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/pasg-20260521x8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
BBDC
Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments
Barings BDC, Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 1.02, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
INAB
IN8bio enters new ATM equity facility with JonesTrading, terminates prior Cantor agreement
IN8BIO, INC.
June 1, 2026, 6:56 AM ET
other_material
Items 1.01, 1.02, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
GPUS
Hyperscale Data terminates ATM sales agreement after raising $24.7M at $0.1793/share
Hyperscale Data, Inc.
May 28, 2026, 6:45 AM ET
other_material
Items 1.02, 7.01, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
HCWB
HCW Biologics terminates Wugen license, regains ex vivo rights to HCW9201/9206 at no cost
HCW Biologics Inc.
May 27, 2026, 8:00 AM ET
other_material
Items 1.02, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
BRCB
Black Rock Coffee Bar secures irrevocable proxy over founder shares; terminates Cynosure voting agreement
Black Rock Coffee Bar, Inc.
May 20, 2026, 4:40 PM ET
other_material
Items 1.01, 1.02, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
AOMR
Angel Oak Mortgage REIT to repurchase $15M of stock from Xylem; board member resigns
Angel Oak Mortgage REIT, Inc.
May 20, 2026, 4:31 PM ET
other_material
Items 1.01, 1.02, 5.02, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
EVC
Entravision and Alexandra Seros mutual terminate cooperation agreement; Strickler stays on board
ENTRAVISION COMMUNICATIONS CORP
May 19, 2026, 9:09 PM ET
other_material
Items 1.02, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
SLN
Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025
Silence Therapeutics plc
May 18, 2026, 5:00 PM ET
other_material
Items 1.01, 1.02, 8.01, 9.01
same SEC item: 1.02
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.